Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma-Reference-Cited by-同舟云学术

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma

Published:2023-02 Issue:2 Volume:4 Page:100915
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Pandey Gaurav Kumar,Landman Nick,Neikes Hannah K.,Hulsman Danielle,Lieftink Cor,Beijersbergen Roderick,Kolluri Krishna Kalyan,Janes Sam M.,Vermeulen Michiel,Badhai Jitendra^ORCID,van Lohuizen Maarten

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference57 articles.

1. A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 Years' experience;Opitz;J. Thorac. Oncol.,2015

2. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021

3. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma;Bott;Nat. Genet.,2011

4. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations;Bueno;Nat. Genet.,2016

5. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs;Carbone;J. Transl. Med.,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis;Nature Communications;2024-07-09

2. Saturation genome editing of BAP1 functionally classifies somatic and germline variants;Nature Genetics;2024-07

3. Loss of RNF2 delays tumour development in BAP1-deficient mesothelioma;2024-04-27

4. Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma;British Journal of Cancer;2024-03-22

5. Dual targeting of EZH2 and Histone Deacetylases in hematological malignancies promotes transcriptional and metabolic deregulation leading to ferroptosis;2024-03-08